Widespread resistance of gram-negative bacilli (GNB) to the aminoglycosides first became apparent at the Minneapolis Veterans Administration Medical Center (MVAMC), a 700-bed acute-care medical-surgical hospital, in the mid1970s (5) . Much like the MVAMC experience, increased resistance among GNB at other institutions has been reported to be associated with outbreaks of infection (3, 5, 7, 14) . Several of these reports indicate that widespread resistance is plasmid mediated via aminoglycoside-inactivating enzymes (3, 7, 14) .
Recently, Levine et al. (10) reported increased amikacin resistance with increased amikacin use. Resistance was reported to be associated with an increased frequency of GNB production of the 6'-N-acetyltransferase [AAC(6')] enzyme (EC 2.3.1.82). The purpose of this study was to determine the prevalence of AAC(6')-mediated resistance at the MVAMC when the use of amikacin was high (mid-1980 until 1985) .
The methods of aminoglycoside control have been described previously (6) (15) .
Twelve Serratia isolates which had been typed for enzymatic resistance were examined for the presence of plasmid DNA with cesium chloride-ethidium bromide density gradients (9, 13) . Plasmid DNA extracted from Serratia isolates was digested with EcoRI restriction endonuclease (New England BioLabs, Inc., Beverly, Mass.), and fragments were separated by gel electrophoresis and stained in 0.5 jig of ethidium bromide (Sigma Chemical Co., St. Louis, Mo.) per ml as previously described (9) . Restriction patterns of plasmids from each organism were compared with that of the previously described endemic gentamicin R plasmid (9) .
A nalidixic acid-resistant Escherichia coli strain, previously used successfully in conjugation experiments with Serratia isolates, was used to detect the conjugal transfer of tobramycin resistance from plasmid-containing Serratia isolates (9) . Mating mixtures were plated on brain heart infusion agar containing 400 ,ug of nalidixic acid per ml and 6 ,ug of tobramycin per ml and were incubated at 37°C. Statistical evaluation was performed by a modified chi-square method (11) .
The percentage of gentamicin and amikacin usage was observed to significantly change with each study period from 1980 through 1984 (P < 0.001) ( Table 1) . Tobramycin use decreased significantly and did not subsequently change when aminoglycoside control policies were started ( Table 1) .
The number of organisms (n = 129) resistant to tobramycin and susceptible to gentamicin during each month of study is shown in Fig. 1 Of 20 Serratia strains tested by the method of Benveniste et al. (1, 2) , all were found to have AAC(6') activity. One strain was found to also possess the phosphorylating enzymes, APH(3')-I and APH(3')-II. Gentamicin MICs for all but 1 of the 20 strains were 2 ,ug/ml or less, and tobramycin MICs were greater than 16 pLg/ml for all strains. All amikacin MICs were within 1 serial dilution of 16 ,ug/ml, which likely represents the inherent variability of the assay.
Almost all (22 of 23) strains typed by the method of aminoglycoside susceptibility profiles (15) possessed the AAC(6') enzyme, confirming the results of the 14C-labeled acetyl coenzyme A transfer method (2). The one strain that did not have AAC(6') activity was found to be susceptible to all aminoglycosides tested. One strain was found to possess the AAC(6') enzyme and the aminoglycoside 2"-nucleotidyltransferase enzyme.
Of 12 strains randomly selected from the previous 20 Serratia strains, only 2 were found to contain plasmid DNA. The EcoRI restriction endonuclease digestion and gel electrophoresis of the isolated plasmid DNA showed the two plasmids to be dissimilar and also unrelated to the endemic gentamicin resistance plasmid at the MVAMC (4, 14) (data not shown). Neither strain transferred tobramycin resistance to E. coli in mating experiments.
We have demonstrated, as have others (15) , that AAC(6') activity is not infrequent, particularly among Serratia isolates. This enzyme has been demonstrated to inactivate amikacin (12) , but the incidence of AAC(6') among Serratia isolates appears to have declined during 4 years of increased amikacin use. This is in contrast to the experience of Levine et al. (10) , who reported an increased incidence of AAC(6') activity after increased amikacin use.
Serratia isolates with AAC(6') activity may express other aminoglycoside-inactivating enzymes as well. If this is so, we might have missed testing some Serratia isolates which were resistant to all three aminoglycosides. However, randomly selected GNB which were resistant to all three (gentamicin, tobramycin, and amikacin) aminoglycosides have also been tested for enzyme activity as described by Benveniste et al. (1, 2) . To date, four of the seven Serratia isolates with this susceptibility pattern have been tested, and three had AAC(6') activity (unpublished data). An additional 9 Serratia isolates with susceptibility patterns similar to those of the 20 isolates tested in this investigation were also tested as part of the random testing program, and 8 expressed AAC(6') activity.
Three differences exist between our experience and that of Levine et al. (i) Organisms which possessed AAC(6') activity at the MVAMC did not express strong phenotypic resistance to amikacin. Amikacin MICs were 16 or 32 jig/ml for 17 of the 22 Serratia strains with AAC(6') activity when tested with supplemented media. The AAC(6') enzyme found among GNB at the MVAMC may have been phenotypically different from that at other medical centers, and the relatively low level of expressed amikacin resistance may We were unable to demonstrate plasmid-mediated transfer of AAC(6') activity among our Serratia isolates. We were able to detect plasmid DNA in only 2 of 12 organisms, and both revealed different restriction patterns. Therefore, we believe that enzyme activity is not likely to be plasmid mediated, but rather is chromosomal in origin as previously reported for Serratia marcescens (8) . (iii) Aminoglycoside usage at our institution has been strictly controlled (Table 1) .
Other centers have ndt been as successful in restricting tobramycin and gentamicin use (10) . All Serratia species that possessed AAC(6') activity had high-level phenotypic resistance to tobramycin (MIC >16 ,ug/ml). Failure to curtail tobramycin use during periods of increased amikacin use could result in an apparent amikacin-associated increased incidence of AAC(6') production. When tobramycin use at the MVAMC was relatively high (April through June 1980, Table 1 ), the incidence of AAC(6') activity was also high. Subsequent restriction of tobramycin use over the next 4 years ( Table 1) was accompanied by a general decline in apparent AAC(6') resistance (Fig. 1) . Differences in mechanisms of resistance transmission, in phenotypic expression of resistance, and in antibiotic control policies make comparison of data from different institutions difficult. We feel that the data from the MVAMC show that aminoglycoside control policies do have an effect on antibiotic resistance patterns among GNB. The relationship between antibiotic policies and bacterial resistance is complex and requires continued investigation.
